CD274 and cancer: Immunotherapies targeting the programmed cell death-1 receptor (PD-1) and its ligand-1 (PD-L1) yielded impressive clinical results in advanced cancers expressing high levels of PD-L1.1,2 However, novel treatments for rare cancers are limited by insufficient patients and trials to establish treatment benefits.